Amgen (AMGN) Q3 2024: Pipeline-Driven R&D Spend Rises 35% as Meritide, Rare Disease, and Biosimilars Expand Growth Levers

2024-10-30 | By EarningsIQ Research

Amgen’s third quarter showcased double-digit sales growth across a diversified portfolio, but the real story is the company’s aggressive pipeline investment, with R&D up 35% and major late-stage programs set to reshape its future revenue mix. Management is leaning into scale and innovation, with obesity, rare disease, and biosimilars all poised to drive the next phase of growth. With a broad phase three Meritide program imminent and multiple late-stage readouts ahead, Amgen’s capital allocation and execution in new indications will define its competitive standing heading into 2025.

Summary

  • Pipeline Acceleration: Amgen is prioritizing broad late-stage trials in obesity, rare disease, and oncology.
  • Portfolio Diversification: Double-digit growth in 10 products underpins resilience across geographies and segments.
  • Capital Allocation Shift: Elevated R&D and manufacturing investments set the stage for outsized innovation-led growth in 2025.

Business Overview

Amgen is a global biotechnology company focused on discovering, developing, manufacturing, and marketing innovative human therapeutics. The business is structured around four major therapeutic areas: oncology (cancer treatments), general medicine (cardiovascular and bone health), inflammation (autoimmune diseases), and rare diseases. Revenue is generated from branded medicines, biosimilars, and a growing rare disease portfolio, with U.S. and international markets both contributing meaningfully. The company’s growth model relies on both lifecycle management of in-market products and advancing a robust pipeline of first-in-class and best-in-class therapies.

Performance Analysis

Amgen delivered 23% year-over-year revenue growth in Q3, reaching $8.5 billion, with 10 products posting double-digit or better sales gains. Excluding the Horizon acquisition, underlying product sales increased 8%, driven by 12% volume growth, reflecting broad-based momentum across geographies and therapeutic areas. The rare disease segment stood out, contributing $1.2 billion in sales, up 21% year-over-year, while innovative oncology products grew 17%. General medicine, led by Repatha and Avenity, posted robust gains, with Repatha’s U.S. prescriber base expanding 50% year-over-year following payer access wins and field force expansion.

Profitability was supported by a 49.6% non-GAAP operating margin, but operating expenses rose 27%, reflecting Horizon integration and stepped-up R&D. R&D investment spiked 35% to $1.4 billion as Amgen accelerated late-stage programs in obesity (Meritide), cardiovascular (Olpaceran), and oncology (Imdeltra, Zaluridamig). The company generated $3.3 billion in free cash flow, up sharply year-over-year, enabling ongoing pipeline investment and capital returns. Integration of Horizon is on track, with $500 million in targeted cost synergies by year three and more than half expected by year-end.

  • Rare Disease Expansion: Sales of Tepeza, Christexa, Uplizna, and Tavneos are in early lifecycle stages, with international launches and new indications driving upside.
  • Biosimilars Momentum: U.S. launches of PavBlue, Weslana, and Bekemvi position Amgen to capitalize on upcoming market entries and supply disruptions.
  • Inflammation Upside: Tespire’s 67% year-over-year growth and COPD program readouts highlight potential to expand into new, high-value indications.

Enbrel and Otezla faced net price pressure, offset by volume growth and stable cash generation. The company’s breadth of brands and pipeline optionality underpin resilience against segment-specific headwinds.

Executive Commentary

"Our in-market medicines performed well in the quarter, with third quarter revenues up 23% to $8.5 billion, and 10 of our products delivering double-digit or better sales growth. We're also rapidly advancing our pipeline with a significant number of potentially first-in-class or best-in-class medicines positioning us for long-term growth."

Bob Bradway, CEO

"We have a strong long-term growth outlook with breadth and depth across each of our four therapeutic areas, including our innovative pipeline and in-market products, serving patients with serious illnesses around the globe. We will continue to allocate capital to innovation first, and with our strong cash flows, also intend to fund our other capital allocation priorities."

Peter Griffith, Chief Financial Officer

Strategic Positioning

1. Obesity and Metabolic Disease Platform Buildout

Meritide, Amgen’s GLP-1/GIP receptor agonist candidate, is the near-term flagship with a broad phase three program in obesity, obesity-related conditions, and type 2 diabetes set to launch. R&D and manufacturing investments are scaling in anticipation of global trials and commercialization. Amgen is also advancing preclinical oral and injectable obesity candidates (including AMG513), targeting both incretin and non-incretin pathways, to diversify its metabolic pipeline and remain competitive as the obesity market matures.

2. Rare Disease Integration and Expansion

Horizon Therapeutics’ portfolio is being rapidly integrated, with dedicated teams and field force reorganization to drive adoption in low-activity thyroid eye disease (TED) and international launches (notably Tepeza in Japan). Pipeline replenishment is underway, leveraging both internal R&D and external innovation, as evidenced by Aplizna’s breakthrough therapy designation in IgG4-related disease and new project launches since the acquisition.

3. Oncology Innovation Engine

Amgen’s oncology franchise is anchored by bispecific T-cell engager (BiTE) molecules (e.g., Blinsito, Imdeltra, Zaluridamig), with label expansions and new phase three trials in small cell lung and prostate cancer. The company is also advancing novel mechanisms (e.g., AMG-193, a PRMT5 inhibitor), positioning itself in high-unmet-need segments and leveraging platform synergies for next-generation oncology assets.

4. Biosimilars as a Growth and Margin Lever

Biosimilars represent a capital-efficient growth driver, with PavBlue (biosimilar to Eylea) and upcoming launches of Weslana and Bekemvi targeting large reference markets. Amgen’s first-mover advantage, broad field force, and reliable supply chain are key differentiators, especially amid competitor supply disruptions.

5. Operational Scale and Capital Discipline

Manufacturing and process development expertise are central to Amgen’s ability to scale new launches (notably for Meritide and biosimilars) without disproportionate capex. The company is balancing elevated R&D investment with disciplined SG&A and targeted debt reduction, aiming to return to pre-acquisition capital structure by 2025.

Key Considerations

This quarter’s results highlight Amgen’s ability to deliver both near-term commercial execution and long-term pipeline-driven growth. The strategic context is one of transformation, with management betting heavily on innovation and new indications to offset legacy pricing headwinds and biosimilar competition.

Key Considerations:

  • Obesity Pipeline Execution: The breadth and differentiation of the Meritide phase three program will determine Amgen’s competitive position in a rapidly crowding obesity market.
  • Rare Disease Scaling: Success in expanding Tepeza and Aplizna into new geographies and indications is critical to realizing the full value of the Horizon acquisition.
  • Biosimilars Commercialization: Timely launches and reliable supply will be essential to capturing share from incumbents facing supply disruptions or pending patent cliffs.
  • R&D and CapEx Leverage: Sustained innovation investment must translate into late-stage pipeline wins without eroding margin discipline or capital flexibility.
  • Pricing and Payer Dynamics: Ongoing net price declines in legacy products (e.g., Enbrel, Otezla) require offset from volume growth, new launches, and geographic expansion.

Risks

Amgen faces execution risk in large-scale phase three trials, especially for Meritide in obesity and diabetes, where competitive intensity and regulatory scrutiny are high. Ongoing net price erosion in established brands and biosimilar entry pose margin and revenue headwinds. Integration of Horizon products carries commercial and operational risk, particularly in scaling field forces and payer access. Elevated R&D and capex must yield pipeline success to justify the capital allocation shift. Macro factors, including healthcare policy and global supply chain disruptions, remain potential sources of volatility.

Forward Outlook

For Q4, Amgen guided to:

  • Lower non-GAAP EPS sequentially due to increased planned investments in pipeline and strategic brands.
  • Tepeza sales expected to be flat to slightly down versus Q3, with full-year sales up roughly 5% year-over-year.

For full-year 2024, management maintained guidance:

  • Total revenues of $33.0 billion to $33.8 billion
  • Non-GAAP EPS of $19.20 to $20.00

Management highlighted several factors that will influence results:

  • Q4 operating expenses expected to be highest of the year as R&D and commercial investments accelerate.
  • Horizon integration synergies and pipeline progress are key to 2025 momentum.

Takeaways

Amgen’s Q3 results demonstrate a deliberate pivot toward pipeline-driven growth, with R&D intensity and operational scale supporting a multi-year innovation cycle. The company’s ability to successfully launch and expand new indications across obesity, rare disease, and oncology will be the primary determinants of future value creation.

  • Pipeline-First Capital Allocation: Elevated R&D and capex underscore a bet on late-stage pipeline success, especially in obesity and rare disease.
  • Commercial Breadth Mitigates Headwinds: Double-digit growth in 10 brands and biosimilars momentum help offset legacy pricing declines and competitive pressures.
  • 2025 Hinges on Execution: Investors should watch for key phase three readouts, Horizon integration milestones, and biosimilar launch traction to gauge the durability of Amgen’s growth narrative.

Conclusion

Amgen enters the final quarter of 2024 with a broad-based growth engine, but its future trajectory depends on delivering pipeline milestones and scaling new launches. Management’s willingness to invest ahead of revenue reflects confidence, but execution risk is rising as the company transitions its portfolio and capital structure.

Industry Read-Through

Amgen’s results signal a sector-wide pivot toward obesity, rare disease, and biosimilars as primary growth engines for large-cap biopharma. The company’s ability to rapidly integrate acquisitions, scale field forces, and invest in late-stage innovation sets a high bar for peers. Ongoing price pressure in legacy brands and the need for capital-efficient biosimilar launches are industry-wide realities. The focus on differentiated, first-in-class assets and global trial execution will define winners as the competitive landscape in obesity and rare disease intensifies. Manufacturing scale, payer access, and field force agility are emerging as critical differentiators for biopharma players seeking to sustain growth beyond 2025.

AMGN Healthcare Biotechnology Obesity Rare disease Biosimilars R&D Pipeline